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ToxicityHuman adenovirus type 5 (Ad5) has been the most popular platform for the development of oncolytic
Ads. Alternative Ad serotypes with low seroprevalence might allow for improved anticancer efﬁcacy in
Ad5-immune patients. We studied the safety and efﬁcacy of rare serotypes Ad6, Ad11 and Ad35. In vitro
cytotoxicity of the Ads correlated with expression of CAR and CD46 in most but not all cell lines. Among
CAR-binding viruses, Ad5 was often more active than Ad6, among CD46-binding viruses Ad35 was generally
more cytotoxic than Ad11 in cell culture studies. Ad5, Ad6, and Ad11 demonstrated similar anticancer
activity in vivo, whereas Ad35 was not efﬁcacious. Hepatotoxicity developed only in Ad5-injected mice.
Predosing with Ad11 and Ad35 did not increase infection of hepatocytes with Ad5-based vector
demonstrating different interaction of these Ads with Kupffer cells. Data obtained in this study suggest
developing Ad6 and Ad11 as alternative Ads for anticancer treatment.
© 2009 Elsevier Inc. All rights reserved.Introduction
Replication-competent adenoviruses (Ads) are being developed as
therapeutic agents for the treatment of cancer based on their lytic life
cycle that allows for destruction of infected cells (Cattaneo et al.,
2008). Human Ad type 5 (Ad5) is the most extensively used platform
for the development of oncolytic Ads and their consequent testing in
preclinical and clinical settings. Replication-competent Ad5-based
vector H101 was recently approved for clinical use via local
administration in patients with head-and-neck carcinoma in China
(Garber, 2006). In most cases, oncolytic Ad5 is used by intratumoral
injection. Systemic treatment with Ad5-based oncolytic viruses faces
additional challenges due to the barriers to efﬁcient virus delivery to
the tumor site(s) (Demers et al., 2003). Administration of high doses
of Ad5-based vectors results in the virus sequestration by the liver
that limits the number of virions capable of reaching the tumor after
systemic injection. The majority of the injected dose was shown to be
taken up and destroyed by the liver macrophages (Kupffer cells)
within the ﬁrst 24 h after the injection (Worgall et al., 1997).
Additionally, infection of hepatocytes results in a dose-dependent
hepatotoxicity (Shashkova et al., 2007) that limits the therapeutic
window of the systemic treatment with Ad5-based oncolytic viruses
(Small et al., 2006).eet SW, Rochester, MN, USA.
ll rights reserved.High global seroprevalence of Ad5 and high Ad5 neutralizing
antibody (NAb) titers in human populations represent another
signiﬁcant concern for the systemic application of Ad5-based vectors.
It is estimated that 37 to 90% of human subjects in Europe, the United
States, Asia, and Africa have Ad5 NAb (Vogels et al., 2003; Holterman
et al., 2004; Nwanegbo et al., 2004). Pre-existing NAb in patients is
expected to inhibit the anticancer activity of intravascularly admin-
istered Ad (Chen et al., 2000). Therefore, it is of a particular interest to
assess the possibility of using Ad serotypes alternative to Ad5 as
oncolytic agents. There are more than 50 currently known Ad
serotypes that are grouped into six subgroups (A through F) based
on a number of properties including hemagglutination characteristics
and DNA sequences. Replication-defective vectors based on Ad
serotypes that have low seroprevalence and do not cross-react with
Ad5 NAb were recently suggested as alternative vehicles for
vaccination and gene therapy (Vogels et al., 2003; Holterman et al.,
2004; Capone et al., 2006; Abbink et al., 2007; Seshidhar et al., 2003).
However, anticancer activity of these serotypes has not been well
characterized.
In this report, wild type (wt) Ad6, Ad11 and Ad35 were studied as
the potential new oncolytic Ads in comparison with wt Ad5. Ad6, 11,
and 35 were selected for their low seroprevalence and for their
differing interactions with cellular receptors and blood factors. Ad5
and Ad6 viruses belong to group C and use Coxsackie-Adenovirus
Receptor (CAR) as primary receptor for cell entry (Bergelson et al.,
1997; Roelvink et al., 1998). Ad11 and Ad35 viruses, belonging to
group B, usemembrane cofactor protein CD46 as a cellular attachment
protein (Segerman et al., 2003; Gaggar et al., 2003). Recently, binding
312 E.V. Shashkova et al. / Virology 394 (2009) 311–320of blood coagulation factor X to Ad hexon was identiﬁed as a major
mechanism of Ad5 infection of hepatocytes in vivo (Waddington et al.,
2008; Kalyuzhniy et al., 2008). Binding of factor X to Ad6 hexon by
surface plasmon resonancewas shown to occurwith the same efﬁcacy
as to Ad5 (Waddington et al., 2008) whereas Ad11 and Ad35 lacked or
had signiﬁcantly reduced binding to factor X (Waddington et al.,
2008; Kalyuzhniy et al., 2008). These data indicate that Ad5 and 6
should both infect liver efﬁciently by binding to blood factors whereas
Ad11 and 35 may not. Variations in the virus-host and the virus-cell
interactions determine the differences in Ad serotype-speciﬁc
tropism, the ability to kill the infected cells, and in the efﬁciency of
production and spread of the progeny virions. These factors have a
potential effect on the oncolytic activity and the safety proﬁle of the
various Ad serotypes. In this study, we provide novel information on
in vitro and in vivo characteristics of Ad6, Ad11, and Ad35 in
comparison with that of Ad5 that allow the development of
alternative Ad serotypes for the treatment of cancer.
Results
Receptor expression and anticancer activity of Ad serotypes in vitro
We studied the in vitro spread and anticancer activity of wild-type
Ad5, Ad6, Ad11, and Ad35 against a range of cancers: human prostate
carcinoma—LNCaP, DU145, PC3; human breast carcinoma—SKBr-3,
MDA-MB-231, MDA-MB-468; human hepatocellular carcinoma—
HepG2, Hep3B; and human ovarian carcinoma—SKOV-3, OVCAR-3.
Given that Ad5 and 6 use CAR as a primary receptor and Ad11 and 35
use CD46 as a receptor, we compared the cell surface expression ofFig. 1. Characterization of cell surface receptor expression proﬁles and cytotoxic activities of A
LNCaP, DU145, and PC3 cells: shaded line—isotype control, grey line—CAR, black line—CD46
measured on day 5 after infection by MTT assay. Data presented as mean±standard deviatthese two receptors to the ability of the viruses to kill each of the cell
lines. Cells were stained with unlabeled CAR or CD46 antibodies and
then detected by ﬂow cytometry after staining with phycoerythrin-
labeled secondary antibody to approximate the relative levels of CAR
and CD46 on the cells. Oncolytic activity was assessed by infecting
each of the cell lines at various multiplicities of infection (MOIs) with
each of the viruses and cell viability was measured by MTT assay
5 days after infection.
Prostate carcinomas
Each of the prostate cancer cell lines appeared to express higher
levels of CD46 than CAR, but this did not generally translate into
higher oncolytic activities by the CD46-binding viruses. LNCaP cells
had 1.5-fold higher percentage of CD46-positive cells relative to CAR-
expressing cells with 3-fold higher mean ﬂuorescence intensity (MFI)
of CD46 vs. CAR suggesting higher CD46 receptor density on the cells
(Fig. 1A and Table 1). The differences between the dose–response
curves were analyzed by ANOVA followed by Tukey's HSD post-hoc
test for pair-wise comparisons. Interestingly, CAR-binding Ad5 and
Ad6 had signiﬁcantly higher cytotoxicity at low MOIs relative to
that of Ad11 and Ad35 (pb0.005 for Ad5 and Ad6 vs. Ad11 and Ad35)
(Fig. 1B). There were no signiﬁcant differences between the activities
of the viruses belonging to the same group (Ad5 vs. Ad6 p=0.455,
Ad11 vs. Ad35 p=0.999). PC3 cells had 2.7-fold higher percentage of
CD46-expressing cells with 15-fold higher MFI as compared to
CAR-positive cells (Fig. 1A and Table 1). In contrast to LNCaP cells,
Ad infectivity proﬁle of PC3 cells correlated with the receptor
expression levels (Fig. 1B). CD46-binding Ad11 and Ad35 hadd serotypes in prostate cancer cell lines. (A) FACS analysis of Ad receptors expressed by
. (B) Cells were infected with Ad serotypes at indicated MOIs (n=3). Cell viability was
ion (SD).
Table 1
Cell surface expression proﬁles of Ad receptors.
Cell origin Cell line CAR CD46
Positive
cells (%)
MFIa Positive
cells (%)
MFIa
Prostate
carcinoma
LNCaP 49.61 8.69 72.96 27.43
DU145 99.37 202.22 99.97 432.89
PC3 35.53 15.3 94.91 230.43
Breast
carcinoma
SKBr-3 97.77 23.14 99.91 34.5
MDA-MB-231 7.91 10.35 75.85 40.69
MDA-MB-468 82.21 20.29 95.4 31.54
Hepatocellular
carcinoma
HepG2 67.15 15.49 82.62 20.47
Hep3B 98.02 90.43 99.15 141.23
Ovarian
carcinoma
SKOV-3 65.94 12.43 99.07 104.29
OVCAR-3 95.39 48.02 98.39 67.17
a Mean ﬂuorescence intensity.
313E.V. Shashkova et al. / Virology 394 (2009) 311–320signiﬁcantly higher cytotoxicity at lowMOIs in this cell line relative to
that of Ad5 and Ad6 (pb0.001). There were no signiﬁcant differences
between dose–response curves for Ad5 and Ad6 (p=0.147),
however, Ad35 was more cytotoxic as compared with Ad11
(pb0.001). The latter indicates the existence of intrinsic differences
in Ad infectivity between the viruses from the same group. In a third
prostate cell line, DU145, expression of both CAR and CD46 was
detected on 100% of the cells with 2-fold higher CD46 cell surface
density levels (Fig. 1A and Table 1). In this cell line, all viruses had
similar dose–response cytotoxicity proﬁles (pN0.3) with exception
of higher cytotoxicity of Ad35 relative to that of Ad6 (p=0.006)
(Fig. 1B).Fig. 2. Characterization of cell surface receptor expression proﬁles and cytotoxic activities of
SKBr-3, MDA-MB-231, and MDA-MB-468 cells: shaded line—isotype control, grey line—CAR
Cell viability was measured on day 5 after infection by MTT assay. Data presented as meanBreast carcinomas
Infection of breast cancer cell lines in general required higherMOIs
for all of the Ads to reach EC50 (Fig. 2) as compared with that in
prostate cancer cell lines (Fig. 1). This might be partially explained by
the low cell surface CAR and CD46 receptor expression levels as
determined by MFI levels on breast vs. prostate cancer cells (Fig. 2A
and Table 1). SKBr-3 cells expressed slightly higher levels of CD46 as
compared to CAR expression levels (Fig. 2A and Table 1). In this cell
line, Ad35 was the most cytotoxic Ad relative to other serotypes
(pb0.001), whereas Ad5, Ad6, and Ad11 were not signiﬁcantly
different from one another (pN0.980) (Fig. 2B). MDA-MB-231 cells
had 9.6-fold higher percentage of CD46-expressing cells and 4-fold
higher MFI relative to those of CAR-expressing cells (Fig. 2A and
Table 1). The differences between the dose–response curves were
analyzed by ANOVA followed by Tukey's HSD post-hoc test for pair-
wise comparisons. There were no signiﬁcant differences in this cell
line between the dose–response curves for Ads from the same group
(p=0.758 for Ad5 vs. Ad6, p=0.935 for Ad11 vs. Ad35) (Fig. 2B). Ad6
had lowest cytotoxicity as compared with that of group B Ads
(p=0.025 vs. Ad11, p=0.005 vs. Ad35), whereas Ad5 had interme-
diate activity that was not different from any other serotype
(p=0.227 vs. Ad11, p=0.068 vs. Ad35). MDA-MB-468 cells
expressed slightly higher levels of CD46 than CAR (Fig. 2A and
Table 1). Ad35 had highest cytotoxic activity in this cell line relative to
other Ad serotypes (pb0.002 vs. Ad5, Ad6, and Ad11) (Fig. 2B). In
contrast, CD46-binding Ad11 had signiﬁcantly lower activity relative
to CAR-binding Ad5 (p=0.038) that was not different from the
activity of CAR-binding Ad6 (p=1.000 for Ad11 vs. Ad6). TheseAd serotypes in breast cancer cell lines. (A) FACS analysis of Ad receptors expressed by
, black line—CD46. (B) Cells were infected with Ad serotypes at indicated MOIs (n=3).
±SD.
314 E.V. Shashkova et al. / Virology 394 (2009) 311–320results demonstrate the lack of direct correlation between the
expression of primary Ad receptors on the cell surface and the
anticancer activity of Ad serotypes in MDA-MB-468 cells in vitro and
suggest that other receptors or intracellular events play a distinct role
in each Ad serotype infection process.
Hepatocellular carcinomas
HepG2 and Hep3B cell lines both expressed CAR and CD46.
However the cell surface receptor levels were higher in Hep3B cells
relative to those in HepG2 cells (Fig. 3A and Table 1). The differences
between the dose–response curves were analyzed by ANOVA
followed by Tukey's HSD post-hoc test for pair-wise comparisons.
There were no signiﬁcant differences between dose–response curves
for Ad5, Ad6, and Ad35 in HepG2 cells (pN0.900) (Fig. 3B). Ad11 had
signiﬁcantly lower cytotoxicity in this cell line relative to that of all
other serotypes (pb0.001). In Hep3B cells, Ad6 had lowest cytotoxi-
city (pb0.010 vs. Ad5, Ad11, and Ad35) while Ad35 had the highest
activity (p≤0.001 vs. Ad5, Ad6, and Ad11) (Fig. 3B). There was no
signiﬁcant difference between the dose–response curves for Ad5 and
Ad11 (p=0.475).
Ovarian carcinomas
In ovarian carcinoma cell line SKOV-3, staining for CD46 demon-
strated 8.4-fold higher MFI than for CAR (Fig. 4A and Table 1). The
differences between the dose–response curves were analyzed by
ANOVA followed by Tukey's HSD post-hoc test for pair-wise
comparisons. The receptor expression proﬁle correlated with higherFig. 3. Characterization of cell surface receptor expression proﬁles and cytotoxic
activities of Ad serotypes in hepatocellular carcinoma cell lines. (A) FACS analysis of Ad
receptors expressed by HepG2 andHep3B cells: shaded line—isotype control, grey line—
CAR, black line—CD46. (B) Cells were infected with Ad serotypes at indicated MOIs
(n=3). Cell viability was measured on day 5 after infection by MTT assay. Data
presented as mean±SD.
Fig. 4. Characterization of cell surface receptor expression proﬁles and cytotoxic
activities of Ad serotypes in ovarian carcinoma cell lines. (A) FACS analysis of Ad
receptors expressed by SKOV-3 and OVCAR-3 cells: shaded line—isotype control, grey
line—CAR, black line—CD46. (B) Cells were infected with Ad serotypes at indicated
MOIs (n=3). Cell viability was measured on day 5 after infection by MTT assay. Data
presented as mean±SD.cytotoxicity of CD46-binding Ads relative to that of CAR-binding
viruses (pb0.001 for Ad11 and Ad35 vs. Ad5 and Ad6) (Fig. 4B). There
was no signiﬁcant difference between dose–response curves for Ad5
and Ad6 (p=0.286), whereas Ad35 was more cytotoxic at low MOIs
than Ad11 (p=0.016). Another ovarian carcinoma cell line, OVCAR-3,
expressed similar levels of CD46 and CAR (Fig. 4A and Table 1) and
comparison of the dose–response curves did not detect signiﬁcant
differences between any of the Ad serotypes in this cell line (pN0.551)
(Fig. 4B).
One-step growth curve
To assess ampliﬁcation ability of Ad serotypes on different cancer
cells, we infected Hep3B, LNCaP, and DU145 cells with 100 virus
particles (vp) of Ad5, Ad6, Ad11, andAd35 for 2 h anddetermined total
virus yields in infectious units (iu) on days 0, 1, 3, 5, and 7 after the
infection (Fig. 5). Under these conditions, all cells are synchronously
infected. All of the viruses produced 103 to 105 infectious progeny
viruses from each cell. When analyzed with Repeated Measures
ANOVA, no signiﬁcant differences were found in the kinetics of the
burst size of any of the Ads in Hep3B (p=0.634) and DU145
(p=0.638) cells. In contrast, virus burst sizes varied signiﬁcantly in
LNCaP cells (p=0.050). Group B Ad11 and Ad35 produced lower
yields relative to group C Ad5 and Ad6 yields in LNCaP cells. These
results could explain lower cytotoxicity of Ad11 and Ad35 in this cell
line (Fig. 1B). These data are in agreement with recently reported
lower replicative capacity of Ad11-based vector in LNCaP cells as
compared with DU145 cells (Sandberg et al., 2009). Cell surface
molecule proﬁling suggested that DU145 cells represent more
Fig. 5. One-step growth curves of Ad serotypes. Hep3B, LNCaP, and DU145 cells were
infected with Ad5, Ad6, Ad11, or Ad35 at MOI of 100 vp/cell for 2 h. After washing three
times, fresh medium was added to the cells (day 0 timepoint). Cells and supernatants
were collected at indicated timepoints and total infectious virus yield was determined
by limiting dilution assay on A549 cells.
315E.V. Shashkova et al. / Virology 394 (2009) 311–320progressed cancer cell type than LNCaP (Liu, 2000) suggesting perhaps
that stage-dependent variations in the intracellular pathways might
explain the inefﬁcient replication of group B Ads in the LNCaP cells.
Oncolytic activity of Ad serotypes in prostate tumor model in vivo
To assess the oncolytic potential of alternative Ad serotypes in vivo,
we tested the viruses by intratumoral and intravenous injection in
established subcutaneous DU145 tumors in nude mice. DU145 were
selected as all of the viruses generated similar burst sizes (Fig. 5), and
had similar EC50 values, although they varied from 68 to 413 (Fig. 1).
Based on in vitro EC50 data, one would predict efﬁcacy vs DU145 of
Ad5NAd35NAd11NAd6. Based on in vitro burst size data, one would
predict similar efﬁcacies by the viruses.
We ﬁrst treated mice bearing DU145 subcutaneous tumors by a
single intratumoral injection of 3× 1010 vp of Ad5, Ad6, Ad11 or Ad35.
Tumor growth was inhibited in all virus-treated groups (Fig. 6A top)
with strongest effects produced by Ad5 and Ad6 (p=0.034 andp=0.025, respectively, vs. Buffer on day 23 after start of treatment).
Ad11 and Ad35 tumor suppressing activity did not reach statistical
signiﬁcance on day 23 (p=0.131 and p=0.104, respectively, vs.
Buffer) but it was not different from that of Ad5 and Ad6 (pN0.9).
Interestingly, when longer term effects of the treatments were
assessed by survival analysis, Ad5, Ad6, and Ad11 were found to
signiﬁcantly prolong the survival of the treated mice (p=0.003,
p=0.004 and p=0.008, respectively, vs. Buffer) whereas Ad35 did
not increase survival times (p=0.26 vs. Buffer) (Fig. 6A bottom). The
median survival time for buffer-treated mice was 34 days, for Ad35
was 48 days, for Ad5 was 62 days, for Ad6 was 62 days, and for Ad11
was 79 days. The increased survival times produced by Ad5, Ad6, or
Ad11 treatment were not statistically different from each other
(pN0.836).
The oncolytic activity of the viruses was next tested for systemic
administration after intravenous (i.v.) injection. It is known that Ad5-
based vectors are rapidly cleared from the bloodstream by liver
macrophages after i.v. injection (Worgall et al., 1997) leading to
reduced efﬁcacy of systemic anticancer treatment (Shashkova et al.,
2008a). Uptake of systemically delivered Ad5 by Kupffer cells results
in death of these cells that prevents further uptake of the second dose
of the virus (Manickan et al., 2006).We applied a two-dose regimen of
systemic treatment of DU145 tumors with the Ad serotypes. A ﬁrst
“predose”was injected i.v. to deplete Kupffer cells and then 4 h later, a
second i.v. dose of the virus was given as in (Shashkova et al., 2008a).
Analysis of the tumor volumes in Ad5, Ad6, and Ad11-treated groups
relative to those in buffer-treated group was performed on day 27
after the start of treatment that was the last day when all of animals in
the buffer-treated group still had tumors of less than 2000mm3 volume
(Fig. 6B top). Systemic treatmentwithAd5andAd6produced signiﬁcant
inhibition of tumor growth (p=0.010 and p=0.001, respectively, vs.
Buffer) with similar levels of tumor suppression (p=0.851 for Ad5 vs.
Ad6). Ad11had intermediate activity after systemic injection (p=0.200
vs. Buffer; p=0.376 vs. Ad5; p=0.071 vs. Ad6). Analysis of tumor
volumes in Ad35-treated group on day 20 demonstrated lack of
signiﬁcant anticancer activity (p=0.999 vs. Buffer).
The median survival time for buffer-treated mice was 36 days, for
Ad35 was 43 days, for Ad5 was 68 days, for Ad6 was 78 days, and for
Ad11was 85 days (Fig. 6B bottom). Systemic treatmentwith Ad5, Ad6,
and Ad11 signiﬁcantly prolonged survival of the mice (p=0.003,
pb0.001, and p=0.023 for Ad5, Ad6, and Ad11, respectively, vs.
Buffer). Ad35 had intermediate activity (p=0.160 vs. Buffer;
p=0.476 vs. Ad5, p=0.085 vs. Ad6, p=0.435 vs. Ad11). There were
no signiﬁcant differences between survival times in Ad5, Ad6, and
Ad11 treated groups (pN0.215).
In summary, in vitro data would have predicted equal oncolytic
activities by the viruses or rank efﬁcacies of Ad5NAd35NAd11NAd6.
Actual in vivo data demonstrated the rank of efﬁcacies of
Ad5=Ad6=Ad11NAd35.
Lack of liver toxicity of Ad6, Ad11, and Ad35 after high-dose injection
into CD46 transgenic mice
The viruses used in this study are fully replication-competent wt
viruses. They would be expected to have off-target toxicities prior to
being modiﬁed for cancer-speciﬁcity by transcriptional or transduc-
tional targeting. To determine hepatotoxicity of Ad serotypes, we
injected CD46 transgenic mice intravenously with high dose
(1.5×1011 vp) of Ad5, Ad6, Ad11, and Ad35 and measured serum
levels of liver enzyme alanine aminotransferase (ALT) on day 3 after
injection (Fig. 7A). CD46 transgenic mice were shown to have human-
like tissue speciﬁcity of CD46 expression (Mrkic et al., 1998) andwere
used to provide Ad11 and Ad35 their cognate receptor that is lacking
in wild-type mice.
Mice injected intravenously with Ad5 became moribund and were
sacriﬁced on day 3. The morbidity correlated with extremely high ALT
Fig. 6. Anticancer activity of Ads in DU145 tumor model. (A) Subcutaneous DU145 tumors (average tumor volume 212 mm3) were injected once intratumorally with 100 μl of buffer
or 3×1010 vp of Ad5, Ad6, Ad11, or Ad35 (n=6 or 7) in 100 μl volume on day 0. (top) Tumor volumes were measured twice a week. Average tumor volumes are shown up to the last
day when all animals were alive in a group. Mice were euthanized when tumor volume reached 2000 mm3. Data presented as mean±standard error (SE). (bottom) Kaplan-Meier
survival curves for mice from (top) were plotted. (B) Mice bearing subcutaneously established DU145 tumors (average tumor volume 345mm3) received two intravenous injections
of 100 μl of buffer or 3×1010 vp of Ad5, Ad6, Ad11, or Ad35 (n=7 or 8) in 100 μl volume on day 0 with 4 h separating the injections. (top) Measurements of tumor volumes were
taken twice aweek. Average tumor volumes are shown up to the last day when all animals were alive in a group. Mice were euthanized when tumor volume reached 2000mm3. Data
presented as mean±SE. (bottom) Kaplan–Meier survival curves for mice from (top) were plotted.
316 E.V. Shashkova et al. / Virology 394 (2009) 311–320levels in these mice (pb0.001 vs. Mock, Ad6, Ad11, and Ad35). In
contrast, Ad6, Ad11, and Ad35 injections did not increase ALT levels
(p=1.000 vs. Mock) demonstrating lack of liver damage induced by
these Ad serotypes.
Binding of hexon to blood factor X was shown to be crucial for Ad5
infection of hepatocytes (Waddington et al., 2008; Kalyuzhniy et al.,
2008; Vigant et al., 2008). We have shown previously that
intervention into this pathway by anticoagulant treatment reduces
hepatotoxicity of oncolytic Ad5-based vector (Shashkova et al.,
2008a). The lack of liver toxicity of Ad11 and Ad35 correlates with
the ﬁnding that these Ad serotypes have weak or absent binding to
factor X (Waddington et al., 2008; Kalyuzhniy et al., 2008). However,
Ad5 and Ad6 were shown to bind factor X with equal efﬁciency by
surface plasmon resonance (Waddington et al., 2008). The difference
in hepatotoxicity proﬁles of Ad5 and Ad6 (Fig. 7A), therefore, was
unexpected. To evaluate the potential mechanism of reduced liver
toxicity of Ad6, we infected HepG2 cells with Ad serotypes in the
presence or absence of factor X and measured cell viability on day 3
after infection. We found that factor X signiﬁcantly increased
cytotoxicity of Ad5 (pb0.001) and Ad6 (p=0.008), but not Ad11
(p=0.799) and Ad35 (p=0.431) (Fig. 7B). These results correlate
with Ad serotype-speciﬁc capability to bind factor X. Interestingly,
presence of factor X mediated signiﬁcantly stronger effect in Ad5-
infected group relative to that in Ad6-infected group (decrease in cell
viability 36% vs. 15% for Ad5 and Ad6, respectively, p=0.002). As
these Ad serotypes bind factor X with equal efﬁciency, the differences
in factor X-mediated potentiation of cytotoxicity suggest the
existence of additional mechanisms inﬂuencing the infection.
Effects of Ad serotypes on Kupffer cells after i.v. injection
We have previously shown that clearance of i.v. injected oncolytic
Ad5-based vector by Kupffer cells reduced activity of systemicanticancer therapy (Shashkova et al., 2008a). It is important, therefore,
to determine whether alternative Ad serotypes also interact with liver
macrophages. Intravenous injection of Ad5-based vectors results in
rapid necrosis of Kupffer cells in mice (Manickan et al., 2006; Xu et al.,
2008). Injection of second dose of Ad5 vector leads to increased
infection of hepatocytes that can be detected by higher transgene
expression (Tao et al., 2001; Shashkova et al., 2008a). Toassesswhether
Ad6, Ad11, andAd35 have similar predosing effects onKupffer cells, we
pre-injectedmicewith buffer or 3×1010 vp of each Ad serotype and 4 h
later injected mice with 3×1010 vp of Ad5-based vector expressing
reporter gene for ﬁreﬂy luciferase. Mice were imaged for luciferase
expression in the liver on days 1 and 3 after the injections (Fig. 8) and
quantiﬁed luminescence levelswere analyzedwith RepeatedMeasures
ANOVA followed by Tukey's HSD test. As expected, predosingwith Ad5
increased luciferase expression from the Ad5 vector in the liver
(p=0.019 vs. Buffer). Interestingly, predosingwith Ad11 andAd35 did
not result in signiﬁcant changes in the luminescence (p=0.997 and
p=1.000 for Ad11 and Ad35, respectively, vs. Buffer). The predosing
effect of Ad5 was signiﬁcantly different from that of Ad11 (p=0.014)
and Ad35 (p=0.025). In contrast, predosing with Ad6 produced
intermediate results with luminescence levels in the liver not different
from the levels in either group (p=0.562 vs. Ad5, p=0.433 vs. Buffer,
p=0.320 vs. Ad11, p=0.456 vs. Ad35).
Discussion
To date, Ad5 has been the most studied Ad serotype used as a
backbone for the development of vectors for vaccinations, anticancer
treatment, and gene therapy. This is partially explained by the
knowledge obtained during the last two decades about Ad5 (Campos
& Barry, 2007; Rux & Burnett, 2004). While recombinant DNA
technologies made possible signiﬁcantly changing natural character-
istics of Ad5 in order to improve its therapeutic activity (Doronin
Fig. 7. Hepatotoxicity of Ad serotypes and effect of factor X on Ad cytotoxicity. (A)
CD46-transgenic C57BL/6 mice were injected intravenously with 100 μl of buffer or
1.5×1011 vp of Ad5, Ad6, Ad11, or Ad35 (n=3) in 100 μl volume on day 0. Blood was
collected on day 3 after injection and serum ALT levels were measured. (B) Ads were
pre-incubated with buffer or factor X for 10 min. at 37°C and then added to HepG2 cells
at 1000 vp/cell. Two hours later the cells were washed and the medium was replaced.
Cell viability was measured on day 3 after infection. Data presented as mean±SD.
⁎p=0.008, ⁎⁎pb0.001, n.s.—not signiﬁcant.
317E.V. Shashkova et al. / Virology 394 (2009) 311–320et al., 2000; Barton et al., 2006; Post et al., 2007; Shashkova et al.,
2008b), other Ad serotypes have been generally neglected as
potentially valuable agents for the treatment of cancer. The existence
of more than 50 Ad serotypes with differences in receptor interac-
tions, blood factor interactions, safety, and seroprevalence suggests
the possibility of increasing the portfolio of therapeutic viruses by
choosing those with most attractive features. In this report we
describe in vitro and in vivo characteristics of wt Ad serotypes 6, 11,
and 35 with regard to the development of these viruses as alternative
or additional to Ad5 oncolytic agents. Low global seroprevalence and
relatively well-known biological characteristics of these Ads suggest
their potential therapeutic value (Vogels et al., 2003; Holterman et al.,
2004; Abbink et al., 2007; Capone et al., 2006; Seshidhar et al., 2003).
Group C Ad5 and Ad6 viruses and group B Ad11 and Ad35 viruses
use CAR and CD46, respectively, as primary receptors for cell entry
(Bergelson et al., 1997; Roelvink et al., 1998; Segerman et al., 2003;
Gaggar et al., 2003). CD46 is ubiquitously expressed on human cells,
whereas CAR expression varies depending on the cell type. It was
recently reported that in addition to CD46, Ad11 uses unidentiﬁed
receptor X that is expressed at high levels on human tumor cells,
whereas Ad35 nearly exclusively uses CD46 for cell infection (Tuve
et al., 2006). Heparan sulfate proteoglycans (HSPG) were shown to
play a role in infection with Ad5 and Ad35 (Dechecchi et al., 2000;
Tuve et al., 2008). Group C Ads use αvβ1,3,5 integrins as secondary
receptors for virus internalization (Wickham et al., 1993; Li et al.,
2001). Additionally, intracellular trafﬁcking pathways differ for CAR-
and CD46-binding viruses (Leopold & Crystal, 2007). It was demon-
strated that group B viruses accumulate in lysosomeswhereas group C
viruses rapidly trafﬁc to the nucleus.We found that infection of human cancer cell lines of prostate,
breast, ovarian, and hepatocellular origin with Ad5, Ad6, Ad11, and
Ad35 resulted in different levels of cytotoxicity. In vitro, Ad5 was
generally more active than Ad6, and Ad35 had higher cytotoxicity as
compared with that of Ad11. The activity of Ads correlated with CAR
and CD46 expression levels in most but not all cell lines. The
cytotoxicity of the viruses did not correlate with the receptor
expression proﬁle in LNCaP cells. Despite lower level of CAR
expression relative to that of CD46, CAR-binding Ad5 and Ad6 had
signiﬁcantly higher activity in LNCaP cells than Ad11 and Ad35. In
addition, group C Ads had up to 100-fold higher burst size in LNCaP
cells relative to that of group B Ads. This data are in agreement with
recently reported lower cytotoxic activity of Ad11-based vector in
LNCaP cells in comparison with other prostate cancer cell lines
(Sandberg et al., 2009) that might be explained by the earlier cancer
stage origin of this cell line (Liu, 2000). In contrast, we have not
observed signiﬁcant differences in the yields of Ad serotypes
produced by infected Hep3B and DU145 cells. Variations in receptor
(s) used for cell entry and intracellular trafﬁcking speciﬁc for a
particular Ad serotype most likely account for the observed
differences in cytotoxicity and growth characteristics of the viruses.
Oncolytic activity of Ad serotypes in vivowas assessed in a prostate
tumor xenograft model. Based on in vitro EC50 data, we would have
predicted efﬁcacy rankings of Ad5NAd35NAd11NAd6. Based on in
vitro burst size data, we would have predicted similar efﬁcacies by all
of the viruses. After single, intratumoral injections, Ad5, Ad6, and
Ad11 signiﬁcantly prolonged survival of the mice. Surprisingly,
treatment with Ad35 did not have signiﬁcant impact on the survival
rates. Similar results were obtained after systemic antitumor
treatment with the Ad serotypes. Therefore, in vitro efﬁcacies did
not absolutely predict in vivo activities.
The results with Ad35 were unexpected as this virus demonstrated
high anticancer activity in vitro. As nude mice do not ubiquitously
express CD46 and DU145 tumor cells express high levels of CD46,
theoretically, it is expected that these tumors cells should be readily
infected with Ad35 in vivo. Systemic injection of Ad35-based vector into
C57BL/6 mice led to extremely low levels of the virus genome in the
liver, lungs, spleen, and bone marrow (Seshidhar et al., 2003) that was
thought to be mediated by the lack of CD46 expression. However, low
transduction efﬁciency of Ad35 vectors was also observed in CD46
transgenic mice (Sakurai et al., 2006) and in nonhuman primates that
ubiquitously express CD46 (Sakurai et al., 2008). Inaccessibility of CD46
for infection due to predominant expression on the basolateral side of
the cells was suggested as a possible mechanism for the discrepancy
between in vitro and in vivo transductional characteristics of Ad35
(Sakurai et al., 2008). While this barrier could mediate lower anticancer
activity of Ad35 applied systemically due to reduced binding of the virus
to polarized endothelial cells, it appears that thismechanismwouldhave
small impact on the transduction of tumor cells after intratumoral virus
delivery. Inefﬁcient anticancer activity of Ad35 after intratumoral
injection, therefore, indicates that other mechanisms are involved in
Ad35 activity in vivo. Future studies are needed to elucidate the details of
Ad35-host interactions to reveal potential strategies to translate high in
vitro anticancer activity of this virus to the corresponding in vivo efﬁcacy.
In contrast to Ad35, CD46-utilizing Ad11 had signiﬁcant oncolytic
activity after intratumoral and intravenous injections. These results
suggest fundamental differences in the biologies of Ad11 and Ad35,
perhaps related to alternate receptor utilization (e.g. receptor X),
different intracellular events, or as yet unknown differences in
pharmacological characteristics.
Ad6 and Ad11 in our experiments had shown anticancer activity
similar to Ad5 after both intratumoral and intravenous injections
suggesting that these Ad serotypes could be successfully used as
additional or alternative to Ad5 oncolytic Ads. To the best of our
knowledge, this is the ﬁrst report on in vivo oncolytic characteristics
of these Ads in comparison with that of Ad5. The feasibility of further
Fig. 8. Effect of Ad predosing on Kupffer cells. ICR mice were predosed intravenously with buffer or 3×1010 vp of Ad5, Ad6, Ad11, or Ad35 (n=4 or 5) followed 4 h later with
intravenous injection of buffer or 3×1010 vp of Ad5-based vector expressing ﬁreﬂy luciferase reporter gene. Luciferase expression was imaged on days 1 and 3 after injection andwas
quantiﬁed. Data presented as mean±SE.
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“directed evolution” approach (Kuhn et al., 2008) and creating a
complex Ad3/Ad11 chimeric virus that had higher efﬁcacy and safety
as compared with the parental viruses.
Ad5 efﬁciently infects hepatocytes in vivo via binding of blood
factor X to a capsid protein hexon (Waddington et al., 2008;
Kalyuzhniy et al., 2008; Vigant et al., 2008). Ad6 hexon was shown
to bind factor X with same efﬁciency as does Ad5 hexon (Waddington
et al., 2008). In contrast, group B Ads do not bind factor X efﬁciently
(Waddington et al., 2008; Kalyuzhniy et al., 2008). From this, we
predicted that subgroup C Ad5 and Ad6 would cause hepatotoxicity
whereas subgroup B Ad11 and Ad35 would not. We found that high
dose i.v. injection of Ad serotypes in CD46 transgenic C57BL/6 mice
produced high serum ALT levels and consequent morbidity only in
Ad5-injected mice. In contrast, mice injected with the same dose of
Ad6, Ad11, or Ad35 did not develop hepatotoxicity. Ad11 and Ad35
genomes were previously shown to accumulate in the liver of CD46-
transgenicmice to levels similar to Ad5 (Stone et al., 2007). Absence of
liver toxicity of group B Ads is in agreement with the fact that these
viruses do not bind blood factor X. However, striking difference
between the levels of liver damage produced by Ad5 and Ad6 cannot
be explained by the differences in factor X binding. Addition of factor
X increased cytotoxicity of both Ad5 and Ad6 in HepG2 cells in vitro
and did not have this effect on Ad11 and A35 activity. These data
conﬁrmed that Ad serotype speciﬁc binding to factor X has functional
effect on replicative virus infection. However, increase in cytotoxicity
mediated by the presence of factor X was higher for Ad5 relative to
Ad6. It is possible that length difference between ﬁber shafts mediates
the outcome of Ad5 and Ad6 infections (Adhikary et al., 2004;
Shayakhmetov & Lieber, 2000). Ad5 ﬁber has 21 β-turn repeatswhereas Ad6 has only 18 (Adhikary et al., 2004); this difference may
affect infection of hepatocytes. Notably, the shaft length difference
does not negatively affect cancer cell infection in vitro or in vivo.
The difference in infectivity by Ad5 and Ad6 is consistent with
observations in humans. Ad5 is responsible for 18.6% of all Ad
infections in humans, compared with only 4% caused by Ad6 (Schmitz
et al., 1983). Ad6 is uncommon in the adenoids and tonsils compared
to other group C Ads (Garnett et al., 2009). In addition, Ad6 is the only
member of group C Ads that has not been observed in immunosup-
pressed patients receiving liver transplants (Kojaoghlanian et al.,
2003). Together with high anticancer activity after local and systemic
administrations, these data suggest the development of Ad6 as a novel
Ad serotype for oncolytic treatment.
Systemic treatment with oncolytic Ad5-based vectors is challeng-
ing due to the sequestration of the majority of the injected virus dose
by liver Kupffer cells (Worgall et al., 1997) resulting in a rapid death of
these cells (Manickan et al., 2006). Depletion of Kupffer cells with Ad5
pre-administration was shown to increase the levels of hepatocyte
transduction with subsequently delivered Ad5-based vectors (Tao
et al., 2001; Shashkova et al., 2008a). It was demonstrated that
scavenger receptors on Kupffer cells are predominantly responsible
for clearance of Ad5 vectors (Xu et al., 2008). Opsonization with
natural antibody and complement was shown to play a contributory
role to this process (Xu et al., 2008). It is not known whether other
Ad serotypes have similar effect on Kupffer cells. As Kupffer cell-
mediated clearance of i.v. injected Ad5 reduces its therapeutic activity,
it is important to determine whether alternative Ad serotypes also
interact with these cells.
We show here that predosing mice with Ad5 and Ad6 increases
transduction of hepatocytes with consequently injected Ad5 vector
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luciferase expression relative to that of Ad6. In contrast, predosing
with Ad11 and Ad35 did not increase transgene expression in the
liver. These data suggest that group C Ads interact with Kupffer cells in
a similar manner whereas group B Ads either are not recognized by
Kupffer cells or do not cause death of these cells. It was reported that
killing of Kupffer cells by Ad5 occurred at post-binding step and was
dependent on the intracellular trafﬁcking of the vector, in particular,
on the ability of the vector to escape endosomes (Smith et al., 2008).
As accumulation of recombinant Ad5 vectors by Kupffer cells did not
differ regardless of their levels of toxicity for Kupffer cells (Smith et al.,
2008), it is possible that group B Ads bind these cells but do not cause
their death due to the slower release from the endosomes (Leopold &
Crystal, 2007). Fiber shaft was also shown to play signiﬁcant role in
depleting Kupffer cells as Ad5 with shorter Ad35 ﬁber was less
effective at killing Kupffer cells (Smith et al., 2008). Shorter Ad6 ﬁber
shaft relative to Ad5 ﬁber shaft (Adhikary et al., 2004)may represent a
possible mechanism for the difference in predosing effects of Ad5 and
Ad6. Further studies are warranted to investigate detailed interactions
of various Ad serotypes with Kupffer cells and other types of cells in
the liver.
In conclusion, we have shown that Ad5, Ad6, Ad11, and Ad35
produce cytotoxicity in various cancer cell lines in vitro. Ad5, Ad6, and
Ad11 had signiﬁcant anticancer activity after intratumoral and
intravenous administration in mice bearing prostate tumor xeno-
grafts. Oncolytic activity of Ad35 was not signiﬁcant in this tumor
model despite the high cytotoxicity observed in vitro. Ad group-
speciﬁc differences in interactionwith Kupffer cells provide additional
information about the biological characteristics of these viruses that is
relevant to their potential use as systemic oncolytic agents. Safety and
efﬁcacy of Ad6 and Ad11 suggest that development of these Ad
serotypes for cancer treatment might be of particular value.
Materials and methods
Cell lines and viruses
Human prostate cancer cell lines PC3, DU145, and LNCaP; human
breast cancer cell lines SKBr-3, MDA-MB-468, and MDA-MB-231;
human ovarian cancer cell lines SKOV-3 and OVCAR-3, human
hepatocellular carcinoma cell lines Hep3B and HepG2, and human
adenocarcinoma A459 were purchased from American Type Culture
Collection (ATCC). All cell lines were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS; HyClone).
Wt Ad5, Ad6, Ad11, and Ad35 were obtained from ATCC. Suspension
KB cells were maintained in HyQ MEM/EBSS (HyClone) supplemen-
ted with 10% FBS andwere used for propagation of the viruses. Double
CsCl banding was used for virus puriﬁcation and vp concentration was
determined by OD260 measurements.
Cell culture studies
Cells were infected with Ad serotypes at various MOIs and cell
viability was measured by MTT assay (Sigma-Aldrich) on day 5 after
the infection. To measure virus burst size, cells in 6-well plates were
infected with Ads at MOI of 100 vp/cell for 2 h in FBS-free medium.
Then cells werewashed three times and fresh FBS-containingmedium
was added to the cells. Cells and supernatants were collected at days 0
(2 h), 1, 3, 5, and 7 after the infection, freeze/thawed three times and
titered on A549 cells by limiting dilution assay (n=3). Twenty-eight
days later, the plates were read and the yields were divided by the
initial number of cells to determine virus burst size. For factor X
binding experiment, Ads were incubated with factor X (Haematologic
Technologies) for 10 min at 37 °C and then added to the cells. Final
concentration of factor X was at physiological level (10 μg/ml). Three
days later, cell viability was determined by MTT assay.Flow cytometry
To determine CAR and CD46 expression proﬁles, cells were
collected with the cell dissociation buffer (Invitrogen Corporation),
stainedwith ﬁrst Ab against CAR (Upstate) or CD46 (BD Pharmingen),
or with isotype IgG1 control Ab (BD Pharmingen). The secondary Ab
was goat anti-mouse IgG conjugated to R-phycoerythrin (Invitro-
gen). Ten thousand cells for each cell line were analyzed by ﬂow
cytometry.
Animals
Outbred ICR female mice (6-9 weeks old) were purchased from
National Cancer Institute. Nude mice (4-6 weeks old) were purchased
from Harlan Sprague Dawley. CD46-transgenic C57BL/6 mice (4-6
weeks old) were kindly provided by Roberto Cattaneo (Mayo Clinic).
Bioluminescence imaging
Mice were anesthetized with ketamine and xylazine and injected
intraperitoneally with 100 μl of D-Luciferin (20 mg/ml) (Molecular
Imaging Products). Images were taken by Kodak In-Vivo F system
(Kodak) and processed and analyzed using Kodak Imaging Software
(Kodak).
Liver toxicity studies
CD46-transgenic C57BL/6 mice were injected intravenously via
the tail vein with 1.5×1011 vp of Ad5, Ad6, Ad11, or Ad35 (n=3) in
100 μl volume on day 0. Blood was collected at day 3 and analyzed for
serum levels of alanine aminotransferase (ALT) by colorimetric
endpoint reaction method according to manufacturer's instructions
(Biotron Diagnostics).
In vivo anticancer activity
DU145 tumors were established by injecting nude mice subcuta-
neously with 1×106 DU145 cells in 200 μl of growth medium
containing 50% Matrigel (BD Biosciences). When average tumor
volume reached 212 or 345 mm3 (24–25 days after cell injection),
mice received single intratumoral injection of 100 μl of buffer or
3×1010 vp of Ads or two intravenous injections of 3×1010 vp
separated by 4 h in 100 μl volume. Tumor dimensions were measured
twice a week with calipers and tumor volumes were calculated as
width2×length×1/2. Mice were euthanized when the tumor volume
reached 2000 mm3.
Statistical analyses
The data were ﬁtted with sigmoid curves and EC50 values were
calculated using GraphPad Prism 4 software. Statistical analyses
were performed using SPSS software. The statistical signiﬁcance
was assessed with factorial ANOVA (in vitro data and in vivo
toxicity data) or repeated measures ANOVA (tumor volume and
predosing with Ad serotypes data) followed by Tukey's HSD test for
pair-wise comparisons between groups. Effect of factor X on in vitro
activity of Ads was analyzed by 2-tailed unpaired t-test. Survival
data were analyzed using the log rank test. p≤0.05 was considered
signiﬁcant.
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